Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benzylpenicillin Concentrations in Intrapartum Group B Streptococcus Prevention Guidelines; A Systematic Review of the Evidence.

The Australian & New Zealand journal of obstetrics & gynaecology·2026
Same author

Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.

Antimicrobial agents and chemotherapy·2026
Same author

Using an RNA binding protein to detect mRNA on lipid nanoparticles.

Scientific reports·2026
Same author

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Research square·2026
Same author

Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Critical care (London, England)·2026
Same author

Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbial Hydrolysates as Amino Acid Source in Cell Culture Media for Cellular Agriculture.

Biotechnology and bioengineering·2026
Same journal

LLM-Guided Parameter Optimization for Mechanistic CHO Cell Bioreactor Models.

Biotechnology and bioengineering·2026
Same journal

Three-Dimensional-Printed Polylactic Acid Scaffolds Coated With a Paeonol-Incorporated Gelatin/Bioactive Glass Composite Layer for Enhanced Osteogenic Performance.

Biotechnology and bioengineering·2026
Same journal

Recent Progress in Antimicrobial Peptides (AMPs) Towards Enhanced Selectivity and Reduced Cytotoxicity by Molecular Engineering.

Biotechnology and bioengineering·2026
Same journal

mZVI-Enhanced Mixed Nitrogen Removal in Klebsiella oxytoca via Coordinated Electron Transfer and Metabolic Reprogramming.

Biotechnology and bioengineering·2026
Same journal

Growth Model for Continuous Culture of a Hydrogen-Oxidizing Bacterium, Hydrogenophilus thermoluteolus Strain TH-1.

Biotechnology and bioengineering·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

Development of Methods to Produce SARS CoV-2 Virus-Like Particles at Scale.

Melissa A Edeling1, Linda Earnest1, Julio Carrera Montoya1

  • 1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Biotechnology and Bioengineering
|February 12, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a rapid, scalable method to produce SARS-CoV-2 virus-like particles (VLPs) for pandemic preparedness. This efficient process ensures quick manufacturing of VLP vaccines and therapeutics.

Keywords:
COVID‐19SARS‐CoV‐2VLPmolecular platformprotein purificationscalabilityvaccinevirus‐like particle

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

Related Experiment Videos

Last Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

Area of Science:

  • Biotechnology
  • Virology
  • Vaccine Development

Background:

  • The SARS-CoV-2 pandemic highlighted the urgent need for rapid development of medical countermeasures.
  • Existing vaccine platforms require significant time for development and manufacturing, posing challenges for pandemic preparedness.

Purpose of the Study:

  • To establish a simple, efficient, and scalable process for producing SARS-CoV-2 virus-like particles (VLPs).
  • To create a molecular platform for rapid manufacturing of medical interventions during pandemics.

Main Methods:

  • Tangential flow filtration using a 100 kDa semi-permeable membrane for concentration and buffer exchange.
  • Anion exchange chromatography for VLP purification.
  • Quality control using Western blot, ELISA, and electron microscopy to confirm VLP integrity and Spike protein presence.

Main Results:

  • Purification of SARS-CoV-2 VLPs completed in under 2 days.
  • Demonstrated successful concentration, purification, and quality control of VLPs.
  • Validated VLP structure and Spike protein display via multiple analytical techniques.

Conclusions:

  • The described VLP production process is adaptable and scalable for manufacturing.
  • This method serves as a roadmap for producing VLPs for preclinical studies and future pandemic preparedness.
  • Rapid VLP production is crucial for timely response to emerging infectious diseases.